Mizuho Upgrades Albemarle to Outperform from Neutral
Fintel reports that on October 14, 2026, Mizuho upgraded their outlook for Albemarle (NYSE:ALB) (XTRA:AMC) from Neutral to Outperform. This rating action follows a prior action by Mizuho on October 1, 2026, where the firm maintained a Neutral rating on the specialty chemicals company. Other recent analyst actions include Barclays initiating coverage on October 13, 2026, with an Equal-Weight rating, Argus Research maintaining a Buy rating on October 7, 2026, and UBS maintaining a Buy rating on October 5, 2026.
Albemarle Corporation, based in the United States, is a global leader in the specialty chemicals industry, with a pronounced emphasis on lithium, bromine, and catalyst solutions. It primarily operates within the lithium sector, focusing on the production and development of lithium compounds which are crucial for rechargeable batteries used in electric vehicles and other technologies. Albemarle's strategic projects include expanding its lithium production capacity through the development of the Kemerton site in Australia and the La Negra site in Chile, responding to the skyrocketing demand for battery-grade lithium. This expansion is part of its broader strategy to maintain and strengthen its position in the rapidly evolving and increasingly competitive battery materials market.
Prior to the upgrade, Albemarle's stock closed at $97.65 on October 13, 2026. The stock has experienced a price change of -8.18% over one week, relative to a baseline close of $106.35 on October 6, 2026. Over a one-month period, the stock registered a price change of -16.91% from a baseline close of $117.52 on September 11, 2026.
As of October 2, 2026, the current consensus target mean for Albemarle was $181.16, with a median target of $178.50. This mean target implies a change of +85.52% from the stock's pricing. This consensus target represents a revision from the prior consensus target mean of $182.86 recorded on September 15, 2026, which is a consensus target revision of -0.93%.
For the current recommendation period of September 1, 2026, the aggregate recommendations consisted of 6 strong buy, 12 buy, and 9 hold recommendations, totaling 27 recommendations. This represents 66.7% positive recommendations and 33.3% hold recommendations. In the prior period of August 1, 2026, there were 6 strong buy, 10 buy, and 10 hold recommendations, totaling 26 recommendations, which represented 61.5% positive and 38.5% hold recommendations.
Albemarle reported its latest earnings on August 5, 2026, with an actual EPS of 3.75, compared to an estimate of 3.2701, representing an EPS surprise of +14.68%. Actual revenue was $1,743,313,000.00, compared to an estimated $1,618,740,281.00. The company's upcoming earnings date is scheduled for November 4, 2026, during the after market close session.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 14, 2026 | Mizuho | Neutral | Outperform | upgrade |
| October 13, 2026 | Barclays | Equal-Weight | initiated coverage | |
| October 7, 2026 | Argus Research | Buy | Buy | maintained |
| October 5, 2026 | UBS | Buy | Buy | maintained |
| October 1, 2026 | Mizuho | Neutral | Neutral | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.